Healthcare Industry News:  Vascular Stent 

Devices Interventional Cardiology

 News Release - October 23, 2006

MIV Therapeutics to Detail Research Results Showing Excellent Performance of Breakthrough Stent Coatings at TCT Conference

Long Term Data Further Validates MIVT's Drug Eluting Stent Technology for Safer CardioVascular Stents Capable of Single or Multiple Drug Delivery


ATLANTA--(HSMN NewsFeed)--MIV Therapeutics (OTCBB:MIVT ; FWB:MIV), announced that Dr. Greg Kaluza, Scientific Director, Center for Research in Cardiovascular Interventions at The Methodist Hospital Research Institute, Houston, TX, who directed the independent preclinical study of MIVT's stent coatings will present recent results of a long-term animal study of its proprietary stent coating technology at the Annual Transcatheter Cardiovascular Therapeutics (TCT) 2006 conference in Washington, D.C., the field's largest scientific meeting.

The latest results extend the evidence of long term safety, biocompatibility and performance of the Company's unique hyrdroxyapatite (HAp) stent coatings.

MIVT's research was one of only three abstracts selected for presentation in its subject area.

According to the conclusions that Dr. Kaluza will present at the TCT meeting, "MIVT's exemplary HAp coating features excellent long term biocompatibility and makes an attractive candidate for next-generation stent coatings."

Other MIV Therapeutics presentations that will be made at the TCT include:

  • The promising results of a first in-vivo study on the use of a non-polymeric lipid based coated stent delivering an antirestenotic agent.

  • The encouraging results of a first in-vivo study of an electrochemically deposited HAp coated stent eluting a combination of multiple antirestenotic drugs.

"These key findings from recent trials have provided the necessary evidence that we have excellent candidates to address the market's demand for a safer drug eluting stent and allows us to move our platforms to the next phase in their development," said Dr. Mark Landy, President of MIV Therapeutics.

TCT is the largest interventional vascular medicine symposium in the world, with attendance by more than 10,000 physicians, health care providers and industry professionals specialized in the field of interventional vascular therapy. TCT has become the premiere venue to introduce groundbreaking and pioneering innovations in this field. Acceptance to present at the conference represents an important recognition of the significance of MIVT's proprietary technology.

"The TCT conference is one of the most important events in our field. Only a small proportion of abstracts are selected every year to be presented as oral presentations at the TCT conference, and I am very pleased that our research was found by TCT's professional reviewers worthy of this exposure," said Dr. Landy. "This strengthens MIVT's growing reputation for scientific leadership as we continue on our path to commercialization and address the market's demand for a safer drug eluting stent."

At the conference, Dr. Kaluza will deliver an abstract entitled, "Exemplary Long-Term (Six Month) Biocompatibility of a Novel Ultra-Thin Hydroxyapatite Stent coating in Normal Porcine Coronary Arteries." Co-authors include chief study pathologist Dr. Fred J. Clubb, Jr. and members of MIVT's research team. The presentation will take place on the 25th October at the TCT in room 145AB at 10:15am.

About Transcatheter Cardiovascular Therapeutics 2006

Transcatheter Cardiovascular Therapeutics (TCT), sponsored by the Cardiovascular Research Foundation®, is a scientifically stimulating symposium for physicians and other health care professionals who specialize in the field of interventional vascular therapy. This year's event is scheduled for October 22-27, 2006, Washington Convention Center, Washington, D.C. For more information, please visit http://www.tct2006.com.

About The Methodist Hospital Research Institute

The Methodist Hospital Research Institute in Houston, TX, is a cornerstone of The Methodist Hospital's strategic vision for its future as a top-ranked academic medical center. The Research Institute is committed to moving the latest discoveries in the laboratory to the bedside in order to provide a new standard of care for our patients in Houston and in other parts of the country. For more information on The Methodist Hospital and the Methodist Hospital Research Institute, see http://www.methodisthealth.com/.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardioVascular Stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for CardioVascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogycapital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.


Source: MIV Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.